

New Venturetec

NET ASSET VALUE - February 28, 2019

Shares issued private	4'500'000	Price: USD 23.83	USD 107'250'000
Shares issued IPO	500'000	Price: CHF 33.00 (ex.rate 1.47)	USD 11'250'000
	5,000,000		USD 118'500'000

Total paid in capital	USD	118'500'000.00
------------------------------	------------	-----------------------

Realized gain* (since inception to date)	USD	75'269'925.93
Realized loss* (since inception to date)	USD	109'585'211.82

*inclusive reinvestments

Investment appreciation of current portfolio companies

Unrealized gain	USD	47'927'536.77
Unrealized loss	USD	0.00
Total appreciation	USD	47'927'536.77

NAV

Cost of investments	USD	28'475'733.64
Appreciation of investments	USD	47'927'536.77
Estimated value of investments	USD	76'403'270.41
Convertible Notes	USD	-13'272'096.91
Loan	USD	-7'690'445.00
Bank Loan	USD	0.00
Accrued expenses	USD	0.00
Accounts receivables	USD	0.00
Cash at bank	USD	89'260.55
Estimated value	USD	55'529'989.05
NAV per share USD		11.11
NAV per share CHF		11.08

Exchange rate USD/CHF	0.9975
Closing Market Price February 28, 2019	CHF 7.30

New Venturetec NAV - February 28, 2019

INDUSTRY/ COMPANY	AMOUNT USD	% CAPITAL	SECURITIES	PRICE COST	PRICE REPORTED	UNREALIZED GAIN (LOSS)	TOTAL EST. VALUE	% NAV
1. Osiris Therapeutics, Inc.	23'780'932.93	83.5	4'103'301 Common Shares	5.80	17.41	47'657'537.48	71'438'470.41	93.4
2. Myriad Genetics	4'694'800.71	16.5	160'000 Shares	29.34	31.03	269'999.29	4'964'800.00	6.5
TOTAL	28'475'733.64	100.0				47'927'536.77	76'403'270.41	99.9